Table 1 Patient demographics (full analysis set)

From: Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study

 

Placebo

n = 85

Esaxerenone 1.25 mg/day

n = 82

Esaxerenone 2.5 mg/day

n = 84

Esaxerenone 5 mg/day

n = 88

Eplerenone 50–100 mg/day

n = 84

All

N = 423

Sex (male), n (%)

60 (70.6)

55 (67.1)

54 (64.3)

65 (73.9)

61 (72.6)

295 (69.7)

Age (years)

57.3 ± 9.1

57.2 ± 9.3

56.8 ± 9.4

57.1 ± 8.8

56.5 ± 10.0

57.0 ± 9.3

Weight (kg)

69.0 ± 13.5

68.8 ± 12.3

67.9 ± 12.1

69.8 ± 13.2

70.7 ± 17.0

69.3 ± 13.7

BMI (kg/m2)

25.5 ± 4.1

25.3 ± 3.7

24.9 ± 3.3

25.7 ± 3.7

25.8 ± 4.9

25.5 ± 4.0

SBP (sitting, mmHg)

156.7 ± 9.0

156.4 ± 9.1

156.4 ± 8.4

157.4 ± 9.0

157.9 ± 8.4

157.0 ± 8.8

DBP (sitting, mmHg)

96.8 ± 5.0

97.2 ± 5.5

98.6 ± 5.6

97.2 ± 5.4

98.4 ± 5.3

97.6 ± 5.4

SBP (ABPM, mmHg)

167.0 ± 12.1

166.2 ± 14.7

165.0 ± 15.5

167.1 ± 15.3

165.9 ± 14.0

166.2 ± 14.3

DBP (ABPM, mmHg)

97.9 ± 7.6

98.9 ± 9.0

98.9 ± 10.0

98.5 ± 7.2

98.3 ± 8.0

98.5 ± 8.3

Pulse rate (bpm)

72.1 ± 9.6

73.3 ± 10.2

73.3 ± 9.5

71.7 ± 9.2

73.8 ± 10.2

72.8 ± 9.7

Prior treatment for hypertensiona, n (%)

44 (51.8)

43 (52.4)

43 (51.2)

50 (56.8)

41 (48.8)

221 (52.2)

Presence of diabetes, n (%)

9 (10.6)

11 (13.4)

8 (9.5)

10 (11.4)

20 (23.8)

58 (13.7)

LDL cholesterol (mg/dL)

129.1 ± 32.6

127.5 ± 31.0

130.4 ± 31.3

132.0 ± 34.4

127.2 ± 30.2

129.3 ± 31.8

Serum K+ (mEq/L)

4.14 ± 0.31

4.07 ± 0.28

4.10 ± 0.25

4.14 ± 0.29

4.09 ± 0.28

4.11 ± 0.29

HbA1c (%)

5.64 ± 0.59

5.67 ± 0.65

5.62 ± 0.63

5.46 ± 0.42

5.76 ± 0.63

5.63 ± 0.60

FPG (mg/dL)

106.3 ± 16.4

109.7 ± 21.2

105.9 ± 17.3

104.2 ± 14.0

109.5 ± 19.9

107.1 ± 17.9

eGFRcreat (mL/min/1.73 m2)

78.0 ± 11.6

77.0 ± 12.2

80.3 ± 11.9

79.6 ± 11.5

81.3 ± 12.2

79.2 ± 11.9

PRA (ng/mL/h)

1.05 ± 0.91

1.10 ± 1.05

1.11 ± 1.00

0.96 ± 1.09

1.09 ± 0.97

1.06 ± 1.00

PAC (pg/mL)

116.5 ± 50.15

112.8 ± 35.68

110.0 ± 37.32

107.5 ± 42.51

113.7 ± 39.85

112.1 ± 41.37

Alcohol consumption, n (%)

 Never

20 (23.5)

24 (29.3)

23 (27.4)

21 (23.9)

25 (29.8)

113 (26.7)

 Former

7 (8.2)

6 (7.3)

3 (3.6)

6 (6.8)

2 (2.4)

24 (5.7)

 Current

58 (68.2)

52 (63.4)

58 (69.0)

61 (69.3)

57 (67.9)

286 (67.6)

  1. Data are presented as mean ± SD, unless otherwise stated
  2. ABPM ambulatory BP monitoring, DBP diastolic blood pressure, eGFRcreat estimated glomerular filtration rate with creatinine, FPG fasting plasma glucose, HbA1c hemoglobin A1c, LDL low-density lipoprotein, PRA plasma renin activity, PAC plasma aldosterone concentration, SBP systolic blood pressure
  3. aWithin 4 weeks prior to run-in period
Back to article page